286 related articles for article (PubMed ID: 27461138)
21. Therapeutic targets of triple-negative breast cancer: a review.
Jamdade VS; Sethi N; Mundhe NA; Kumar P; Lahkar M; Sinha N
Br J Pharmacol; 2015 Sep; 172(17):4228-37. PubMed ID: 26040571
[TBL] [Abstract][Full Text] [Related]
22. Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.
Stewart DA; Winnike JH; McRitchie SL; Clark RF; Pathmasiri WW; Sumner SJ
J Proteome Res; 2016 Sep; 15(9):3225-40. PubMed ID: 27447733
[TBL] [Abstract][Full Text] [Related]
23. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
Yuan Z; Jiang H; Zhu X; Liu X; Li J
Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
[TBL] [Abstract][Full Text] [Related]
24. SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Llombart-Cussac A; Bermejo B; Villanueva C; Delaloge S; Morales S; Balmaña J; Amillano K; Bonnefoi H; Casas A; Manso L; Roché H; Gonzalez-Santiago S; Gavilá J; Sánchez-Rovira P; Di Cosimo S; Harbeck N; Charpentier E; Garcia-Ribas I; Radosevic-Robin N; Aura C; Baselga J
Breast Cancer Res Treat; 2015 Nov; 154(2):351-7. PubMed ID: 26536871
[TBL] [Abstract][Full Text] [Related]
25. Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer.
Godugu C; Doddapaneni R; Safe SH; Singh M
Eur J Pharm Biopharm; 2016 Nov; 108():168-179. PubMed ID: 27586082
[TBL] [Abstract][Full Text] [Related]
26. Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article.
Khalifa AM; Elsheikh MA; Khalifa AM; Elnaggar YSR
J Control Release; 2019 Oct; 311-312():125-137. PubMed ID: 31476342
[TBL] [Abstract][Full Text] [Related]
27. Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
[TBL] [Abstract][Full Text] [Related]
28. Triple-negative breast cancer: molecular subtypes and new targets for therapy.
Lehmann BD; Pietenpol JA; Tan AR
Am Soc Clin Oncol Educ Book; 2015; ():e31-9. PubMed ID: 25993190
[TBL] [Abstract][Full Text] [Related]
29. Recent Advances of Nanotechnology in the Diagnosis and Therapy of Triple- Negative Breast Cancer (TNBC).
Kanugo A; Gautam RK; Kamal MA
Curr Pharm Biotechnol; 2022; 23(13):1581-1595. PubMed ID: 34967294
[TBL] [Abstract][Full Text] [Related]
30. Nanosoldiers: A promising strategy to combat triple negative breast cancer.
Pawar A; Prabhu P
Biomed Pharmacother; 2019 Feb; 110():319-341. PubMed ID: 30529766
[TBL] [Abstract][Full Text] [Related]
31. Recent therapeutic trends and promising targets in triple negative breast cancer.
Hwang SY; Park S; Kwon Y
Pharmacol Ther; 2019 Jul; 199():30-57. PubMed ID: 30825473
[TBL] [Abstract][Full Text] [Related]
32. The Na⁺/H⁺ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells.
Amith SR; Wilkinson JM; Baksh S; Fliegel L
Oncotarget; 2015 Jan; 6(2):1262-75. PubMed ID: 25514463
[TBL] [Abstract][Full Text] [Related]
33. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
34. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
[TBL] [Abstract][Full Text] [Related]
35. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
[TBL] [Abstract][Full Text] [Related]
36. RIP2 enhances cell survival by activation of NF-ĸB in triple negative breast cancer cells.
Jaafar R; Mnich K; Dolan S; Hillis J; Almanza A; Logue SE; Samali A; Gorman AM
Biochem Biophys Res Commun; 2018 Feb; 497(1):115-121. PubMed ID: 29421659
[TBL] [Abstract][Full Text] [Related]
37. Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances.
Miller-Kleinhenz JM; Bozeman EN; Yang L
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(6):797-816. PubMed ID: 25966677
[TBL] [Abstract][Full Text] [Related]
38. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
39. Nanotechnology, in silico and endocrine-based strategy for delivering paclitaxel and miRNA: Prospects for the therapeutic management of breast cancer.
Ansari MA; Thiruvengadam M; Farooqui Z; Rajakumar G; Sajid Jamal QM; Alzohairy MA; Almatroudi A; Alomary MN; Chung IM; Al-Suhaimi EA
Semin Cancer Biol; 2021 Feb; 69():109-128. PubMed ID: 31891780
[TBL] [Abstract][Full Text] [Related]
40. Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment.
Yu D; Li W; Zhang Y; Zhang B
Biomed Pharmacother; 2016 Oct; 83():1428-1435. PubMed ID: 27592131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]